**Regularly Scheduled Series**

**You are invited to the OUHSC Department of Pediatrics Grand Rounds**

**Course No. 22D06**

**Wednesday, December 8, 2021**

**12:15 – 1:15pm**

**To Record Your Attendance:  Text XXXXX to 405-562-5828 during Grand Rounds**

***You will still need to text in your attendance to receive CME and access the survey.***

Participants can text in 15 minutes before the scheduled start, all during, and 45 minutes after the scheduled end.

**\* \* \*VIRTUAL\* \* \***

Join Zoom Meeting

**<https://zoom.us/j/91902110932>**

Meeting ID: **919 0211 0932**

Password: **00001111**

One Tap Mobile:  US: +16692192599,,91902110932#,,,,\*00001111# or +16699006833,,91902110932#,,,,\*00001111#

**NOTE**: : The meeting host will admit you to the meeting a few minutes before 12:15.

If you login early, please wait to be admitted.

**Attending a Zoom meeting**:

If you have not yet attended a Zoom meeting then please visit this site (below) for information you will need: <https://support.zoom.us/hc/en-us/articles/201362193-Joining-a-Meeting>

Title:

**“Youth Onset Type 2 Diabetes:**

**Treatments, Complications, and the Path to Improved Outcomes”**

- - - - - - - - - - - - - - - - - - - -

Presented by:

**Jeanie B. Tryggestad, MD**

Associate Professor of Pediatrics, Section Diabetes/ Endocrinology

Children’s Hospital Foundation Paul and Ruth Jonas Chair in Pediatric Diabetes/Endocrinology

Invited by: Pediatric Diabetes/Endocrinology

OUHSC Department of Pediatrics

**Professional Practice Gap:**

Practitioners fail to intensify treatment early in youth onset type 2 diabetes.

Practitioners may not know the rates of complications in youth onset type 2 diabetes.

Practitioners fail to begin screening for diabetes related complications at diagnosis in youth with type 2 diabetes.

**Learning Objectives:** Upon completion of this session, participants will improve their competence and performance by being able to:

 Examine the trends in youth onset diabetes prevalence over the past 20 years.

 Describe the progression of youth onset T2DM.

 Recognize the complications that arise in youth onset T2DM

 Identify the available treatment modalities available for youth onset T2DM

**If you wish to view video tapes of past GR, go to** <https://mediasite.ouhsc.edu/Mediasite/Channel/ch-pedsgr>

Note: We do not have permission from all presenters to videotape their presentations.

**A list of upcoming Pediatric GR topics can be found at:** <https://medicine.ouhsc.edu/Academic-Departments/Pediatrics/Research-Education/Grand-Rounds>

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABP MOC RECOGNITION STATEMENT**

Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.00 MOC point in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

All ABP MOC credits will be reported at the end of the fiscal year on your behalf.

For information about ACCME accreditation and ABP MOC for this activity, please email **myrna-page@ouhsc.edu**.

By providing your ABP number, you consent to have the OUHSC CPD Office submit your participation in this activity to the ABP through the ACCME PARS system.

**LEARNING FORMAT**

Live Virtual and In-Person Activity

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**Nondiscrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides. Inquiries regarding non-discrimination policies may be directed to: Shaniqua Crawford, JD, Institutional Equity Officer and Title IX Coordinator, 405-325-3546, [scrawford@ou.edu](file:///%5C%5Cpedsis%5Cpeds%5Cdata%5CChair%5CChair%5CAdministrative%20Coordinator%5CGrand%20Rounds%5CGrand%20Rounds%20FY%202021-2022%5CWeekly%20Flyer%5Cscrawford%40ou.edu), or visit [www.ou.edu/eoo.html](file:///%5C%5Cpedsis%5Cpeds%5Cdata%5CChair%5CChair%5CAdministrative%20Coordinator%5CGrand%20Rounds%5CGrand%20Rounds%20FY%202021-2022%5CWeekly%20Flyer%5Cwww.ou.edu%5Ceoo.html).

**Accommodation Statement:** For accommodations, please contact Cindy Dibler at Cindy-Dibler@ouhsc.edu.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 This activity received no commercial or in-kind support.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  | **Nature of the Financial Relationship** |   |
| --- | --- | --- |
| **Role** | **First Name** | **Last Name** | **Ineligible Company** | **What was received?** | **For what role?** |   |
|   | Planning Member/ Moderator | H. Christine | Allen, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Muhammad A. | Altaf, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator/Presenter | Ami B. | Bax, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Sanjay I. | Bidichandani, MBBS, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Amanda L. | Bogie, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Co-Course Director/ Moderator | Stephanie D. | DeLeon, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Course Contact | Cindy G. | Dibler | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Morris R. | Gessouroun, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Course Director/ Moderator | Casey N.  | Hester, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Janna M. | Journeycake, MD, MSCS | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Amy B. | Middleman, MD, MSEd, MPH | Up to Date | Royalties | Section Editor/Author |   |
|   | Pfizer | Research fund to OUHSC | PI |   |
|   | **Planner/Moderator**: The conflict was resolved by Dr. Middleman agreeing to recuse herself from planning content in the conflicted area and limiting her role to the introduction of presenters, fielding questions and moderating the flow of discussion between participants and presenters. |   |
|   | Planning Member/ Moderator | Edward D. | Overholt, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Committee / Moderator | Ana I. | Ana I. Quintero-Del Rio, MD, MPH, FAAP | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Jane F. | Silovsky, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | David P.  | Sparling, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Trent E. | Tipple, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|  | Presenter | Jeanie B. | Tryggestad, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |  |
|   | Planning Member/ Moderator | Donna L. | Tyungu, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|   | Planning Member/ Moderator | Ikuyo  | Yamaguchi, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |   |
|  |  |  |  |  |